{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:44:16Z","timestamp":1790307856076,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI106878"],"award-info":[{"award-number":["AI106878"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI155414"],"award-info":[{"award-number":["AI155414"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI177075"],"award-info":[{"award-number":["AI177075"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["TW005572"],"award-info":[{"award-number":["TW005572"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["TW010362"],"award-info":[{"award-number":["TW010362"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.06.052","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T07:34:26Z","timestamp":1688196866000},"page":"4967-4977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry"],"prefix":"10.1016","volume":"41","author":[{"given":"Meagan","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Mandlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-1849","authenticated-orcid":false,"given":"Richelle C.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-8090","authenticated-orcid":false,"given":"Smriti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-7153","authenticated-orcid":false,"given":"Stephen B.","family":"Calderwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-0801","authenticated-orcid":false,"given":"Daniel T.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-6706","authenticated-orcid":false,"given":"Rajib","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamrul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-673X","authenticated-orcid":false,"given":"Mohammad","family":"Kamruzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahima","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Khanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie F.","family":"Vann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraful Islam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taufiqur Rahman","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-9888","authenticated-orcid":false,"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Vortherms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-5694","authenticated-orcid":false,"given":"Robert","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-3449","authenticated-orcid":false,"given":"Pavol","family":"Kov\u00e1\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0059","authenticated-orcid":false,"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2023.06.052_b0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990\u20132016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.052_b0010","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.pcl.2017.03.006","article-title":"The burden and etiology of diarrheal illness in developing countries","volume":"64","author":"Kotloff","year":"2017","journal-title":"Pediatr Clin North Am"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.052_b0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.052_b0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrmicro1662","article-title":"Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.052_b0030","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.052_b0035","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/516452","article-title":"Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection","volume":"175","author":"Robin","year":"1997","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.052_b0040","article-title":"Detoxified O-specific polysaccharide (O-SP)-protein conjugates: emerging approach in the shigella vaccine development scene","volume":"10","author":"Cohen","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2023.06.052_b0045","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1017\/S0950268814000260","article-title":"Recent trends in the epidemiology of shigellosis in Israel","volume":"142","author":"Cohen","year":"2014","journal-title":"Epidemiol Infect"},{"issue":"9046","key":"10.1016\/j.vaccine.2023.06.052_b0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0055","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jcm.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.052_b0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2023.06.052_b0065","article-title":"The shigella vaccines pipeline","volume":"10","author":"MacLennan","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.052_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009826","article-title":"Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes","volume":"15","author":"Citiulo","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.052_b0075","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.052_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.06.052_b0085","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3389\/fimmu.2017.01884","article-title":"A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country","volume":"8","author":"Obiero","year":"2017","journal-title":"Front Immunol"},{"issue":"36","key":"10.1016\/j.vaccine.2023.06.052_b0090","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study","volume":"33","author":"Hatz","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2023.06.052_b0095","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0100","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/acs.bioconjchem.5b00617","article-title":"A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity","volume":"27","author":"van der Put","year":"2016","journal-title":"Bioconjug Chem"},{"issue":"32","key":"10.1016\/j.vaccine.2023.06.052_b0105","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2018.06.063","article-title":"A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei","volume":"36","author":"Frenck","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.052_b0110","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CVI.00665-15","article-title":"Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults","volume":"23","author":"Pitisuttithum","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/IAI.72.2.923-930.2004","article-title":"Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers","volume":"72","author":"Katz","year":"2004","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.052_b0120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/21645515.2019.1575165","article-title":"A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children","volume":"15","author":"Raqib","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.052_b0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum Vaccin"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.052_b0130","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2010.10.035","article-title":"Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh","volume":"29","author":"Rahman","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.052_b0135","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00683-13","article-title":"Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine","volume":"21","author":"Kaminski","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/CVI.00608-15","article-title":"Evaluation of the safety, tolerability, and immunogenicity of an oral, inactivated whole-cell Shigella flexneri 2a vaccine in healthy adult subjects","volume":"23","author":"Chakraborty","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0145","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00583-17","article-title":"Assembly, biochemical characterization, immunogenicity, adjuvanticity, and efficacy of shigella artificial invaplex","volume":"3","author":"Turbyfill","year":"2018","journal-title":"mSphere"},{"issue":"12","key":"10.1016\/j.vaccine.2023.06.052_b0150","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1128\/IAI.68.12.6624-6632.2000","article-title":"Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine","volume":"68","author":"O'Brien","year":"2000","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.052_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.01020-21","article-title":"Immunization of Rabbits with a Quadrivalent Shigella Bioconjugate Vaccine Induces Functional Antibodies Reactive with Shigella Isolates from Kenya","volume":"7","author":"Odundo","year":"2022","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0160","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/acscentsci.1c01479","article-title":"The first-in-human synthetic glycan-based conjugate vaccine candidate against Shigella","volume":"8","author":"van der Put","year":"2022","journal-title":"ACS Cent Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.052_b0165","article-title":"Toward a multivalent synthetic oligosaccharide-based conjugate vaccine against shigella: state-of-the-art for a monovalent prototype and challenges","volume":"10","author":"Phalipon","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.052_b0170","article-title":"Safety and immunogenicity of a shigella bivalent conjugate vaccine (ZF0901) in 3-month- to 5-year-old children in China","volume":"10","author":"Mo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.06.052_b0175","doi-asserted-by":"crossref","first-page":"103343","DOI":"10.1016\/j.ebiom.2021.103343","article-title":"Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection","volume":"66","author":"Raqib","year":"2021","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0180","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2023.06.052_b0185","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1016\/j.vaccine.2021.10.005","article-title":"Scalable production and immunogenicity of a cholera conjugate vaccine","volume":"39","author":"Jeon","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.052_b0190","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.4269\/ajtmh.20-1511","article-title":"Parenteral vaccination with a cholera conjugate vaccine boosts vibriocidal and anti-OSP responses in mice previously immunized with an oral cholera vaccine","volume":"104","author":"Akter","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.06.052_b0195","article-title":"Isolation, purification, characterization and direct conjugation of the lipid a-free lipopolysaccharide of vibrio cholerae O139","author":"Xu","year":"2019","journal-title":"Chemistry"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.052_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003881","article-title":"A cholera conjugate vaccine containing O-specific polysaccharide (OSP) of V. cholerae O1 inaba and recombinant fragment of tetanus toxin heavy chain (OSP:rTTHc) induces serum, memory and lamina proprial responses against osp and is protective in mice","volume":"9","author":"Sayeed","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002683","article-title":"Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide","volume":"8","author":"Alam","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.052_b0210","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1021\/bc2001984","article-title":"Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines","volume":"22","author":"Xu","year":"2011","journal-title":"Bioconjug Chem"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.052_b0215","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cbic.201600699","article-title":"Conjugate vaccines from bacterial antigens by squaric acid chemistry: a closer look","volume":"18","author":"Xu","year":"2017","journal-title":"Chembiochem"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.052_b0220","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/glycob\/cwr088","article-title":"Lipopolysaccharide core structures and their correlation with genetic groupings of Shigella strains. A novel core variant in Shigella boydii type 16","volume":"21","author":"Knirel","year":"2011","journal-title":"Glycobiology"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.052_b0225","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/jcm.26.7.1343-1348.1988","article-title":"Congo red binding and salt aggregation as indicators of virulence in Shigella species","volume":"26","author":"Qadri","year":"1988","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2023.06.052_b0230","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1128\/CVI.00321-12","article-title":"Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera","volume":"19","author":"Johnson","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2023.06.052_b0235","doi-asserted-by":"crossref","unstructured":"Xu P, K.P. In: Bacterial Polysaccharides, Methods and Protocols, E.B. I, editor. 2019, Humana Press: Kingston, ON, Canada. p. 89\u201398.","DOI":"10.1007\/978-1-4939-9154-9_8"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0240","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/iai.51.2.696-698.1986","article-title":"The use of mice in the Sereny test as a virulence assay of shigellae and enteroinvasive Escherichia coli","volume":"51","author":"Murayama","year":"1986","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0245","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1128\/IAI.67.4.2001-2004.1999","article-title":"Adaptive immune response to Shigella flexneri 2a cydC in immunocompetent mice and mice lacking immunoglobulin A","volume":"67","author":"Mansfield","year":"1999","journal-title":"Infect Immun"},{"issue":"19","key":"10.1016\/j.vaccine.2023.06.052_b0250","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.00968-21","article-title":"Outer membrane vesicles derived from salmonella enterica serotype typhimurium can deliver Shigella flexneri 2a O-polysaccharide antigen to prevent Shigella flexneri 2a infection in mice","volume":"87","author":"Tian","year":"2021","journal-title":"Appl Environ Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0255","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/infdis\/jit399","article-title":"A mouse model of shigellosis by intraperitoneal infection","volume":"209","author":"Yang","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0260","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/jcm.31.2.454-457.1993","article-title":"Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients","volume":"31","author":"Cam","year":"1993","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.052_b0265","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1128\/jcm.27.1.162-167.1989","article-title":"Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections","volume":"27","author":"Cohen","year":"1989","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0270","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1365-3083.2002.01079.x","article-title":"Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults","volume":"55","author":"Raqib","year":"2002","journal-title":"Scand J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.052_b0275","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/iai.61.6.2390-2395.1993","article-title":"Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models","volume":"61","author":"Orr","year":"1993","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0280","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.4049\/jimmunol.1302743","article-title":"Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes","volume":"192","author":"Heine","year":"2014","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.052_b0285","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"McGhee","year":"1999","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2023.06.052_b0290","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/infdis\/159.6.1126","article-title":"Inoculum size in shigellosis and implications for expected mode of transmission","volume":"159","author":"DuPont","year":"1989","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2023.06.052_b0295","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1089\/mdr.2018.0229","article-title":"Dissemination of multidrug-resistant Shigella flexneri and Shigella sonnei with Class 1, Class 2, and atypical Class 1 Integrons in China","volume":"25","author":"Kang","year":"2019","journal-title":"Microb Drug Resist"},{"issue":"8","key":"10.1016\/j.vaccine.2023.06.052_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002055","article-title":"South Asia as a reservoir for the global spread of ciprofloxacin-resistant Shigella sonnei: A cross-sectional study","volume":"13","author":"Chung The","year":"2016","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0305","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3201\/eid2302.161203","article-title":"Increasing antibiotic resistance in Shigella spp. from Infected New York City Residents, New York, USA","volume":"23","author":"Murray","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.052_b0310","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.eclinm.2021.101076","article-title":"Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults","volume":"39","author":"Frenck","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2023.06.052_b0315","doi-asserted-by":"crossref","first-page":"103310","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0320","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/vaccines10040548","article-title":"From concept to clinical product: a brief history of the novel shigella invaplex vaccine's refinement and evolution","volume":"10","author":"Turbyfill","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"Supplement_8","key":"10.1016\/j.vaccine.2023.06.052_b0325","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1093\/cid\/ciz909","article-title":"Consensus report on shigella controlled human infection model: immunological assays","volume":"69","author":"Kaminski","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Supplement_8","key":"10.1016\/j.vaccine.2023.06.052_b0330","article-title":"Consensus report on shigella controlled human infection model: introduction and overview","volume":"69","author":"MacLennan","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Supplement_8","key":"10.1016\/j.vaccine.2023.06.052_b0335","article-title":"Consensus report on shigella controlled human infection model: clinical endpoints","volume":"69","author":"MacLennan","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Supplement_8","key":"10.1016\/j.vaccine.2023.06.052_b0340","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz892","article-title":"Consensus report on shigella controlled human infection model: conduct of studies","volume":"69","author":"Talaat","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.06.052_b0345","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1574-6976.2008.00114.x","article-title":"Structure and genetics of Shigella O antigens","volume":"32","author":"Liu","year":"2008","journal-title":"FEMS Microbiol Rev"},{"issue":"19","key":"10.1016\/j.vaccine.2023.06.052_b0350","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1073\/pnas.0900891106","article-title":"Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates","volume":"106","author":"Robbins","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.052_b0355","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.carres.2009.01.004","article-title":"A similarity in the O-acetylation pattern of the O-antigens of Shigellaflexneri types 1a, 1b, and 2a","volume":"344","author":"Perepelov","year":"2009","journal-title":"Carbohydr Res"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0360","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1574-695X.2012.01000.x","article-title":"Shigella flexneri O-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity","volume":"66","author":"Perepelov","year":"2012","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"24","key":"10.1016\/j.vaccine.2023.06.052_b0365","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C3OB42586J","article-title":"Non-stoichiometric O-acetylation of Shigella flexneri 2a O-specific polysaccharide: synthesis and antigenicity","volume":"12","author":"Gauthier","year":"2014","journal-title":"Org Biomol Chem"},{"issue":"11","key":"10.1016\/j.vaccine.2023.06.052_b0370","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.3390\/microorganisms9112360","article-title":"Impact of O-Acetylation on S. flexneri 1b and 2a O-Antigen Immunogenicity in Mice","volume":"9","author":"Arato","year":"2021","journal-title":"Microorganisms"},{"issue":"31","key":"10.1016\/j.vaccine.2023.06.052_b0375","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.1002\/chem.201600567","article-title":"Detailed investigation of the immunodominant role of O-antigen stoichiometric O-acetylation as revealed by chemical synthesis, immunochemistry, solution conformation and STD-NMR spectroscopy for Shigella flexneri 3a","volume":"22","author":"Boutet","year":"2016","journal-title":"Chemistry"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.052_b0380","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00146-18","article-title":"Development, interlaboratory evaluations, and application of a simple, high-throughput shigella serum bactericidal assay","volume":"3","author":"Nahm","year":"2018","journal-title":"mSphere"},{"issue":"5","key":"10.1016\/j.vaccine.2023.06.052_b0385","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3329\/jhpn.v29i5.8896","article-title":"Differential host immune responses to epidemic and endemic strains of Shigella dysenteriae type I","volume":"29","author":"Sayem","year":"2011","journal-title":"J Health Popul Nutr"},{"issue":"7","key":"10.1016\/j.vaccine.2023.06.052_b0390","first-page":"2057","article-title":"Differences among Shigella spp. in susceptibility to the bactericidal activity of human serum","volume":"134","author":"Okamura","year":"1988","journal-title":"J Gen Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.052_b0395","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1172\/JCI104029","article-title":"A study of the relationship of the normal bactericidal activity of human serum to bacterial infection","volume":"39","author":"Roantree","year":"1960","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0400","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00412-16","article-title":"Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study","volume":"24","author":"Shimanovich","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2023.06.052_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"12","key":"10.1016\/j.vaccine.2023.06.052_b0410","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.052_b0415","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/iai.2.1.29-37.1970","article-title":"Antibody responses in serum, secretions, and urine of man after parenteral administration of vaccines","volume":"2","author":"Sirisinha","year":"1970","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2023.06.052_b0420","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/jb.92.1.17-22.1966","article-title":"Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine","volume":"92","author":"Formal","year":"1966","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.06.052_b0425","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3181\/00379727-125-32087","article-title":"Failure of parenteral vaccines to protect monkeys against experimental shigellosis","volume":"125","author":"Formal","year":"1967","journal-title":"Proc Soc Exp Biol Med"},{"issue":"3","key":"10.1016\/j.vaccine.2023.06.052_b0430","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/164.3.533","article-title":"Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei","volume":"164","author":"Formal","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.052_b0435","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0076-6879(94)35129-5","article-title":"Experimental keratoconjunctivitis (Sereny) assay","volume":"235","author":"Kopecko","year":"1994","journal-title":"Methods Enzymol"},{"issue":"24","key":"10.1016\/j.vaccine.2023.06.052_b0440","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.vaccine.2013.04.012","article-title":"Parenteral immunization with IpaB\/IpaD protects mice against lethal pulmonary infection by Shigella","volume":"31","author":"Martinez-Becerra","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23007387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23007387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:28:57Z","timestamp":1759404537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23007387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":88,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23007387"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}